RATIONALE
Recent empirical research suggests isoniazid may lead to a risk reduction ...
INTRODUCTION
In 2022, the WHO conditionally recommended the use of treatment decision algorithms (TDAs) for treatment decision-making in children <10 years with...
BACKGROUND
Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment ...
People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...
BACKGROUND
In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...
BACKGROUND
The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...
BACKGROUND
The optimal dosing strategy of linezolid for treating multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remains unclear. We condu...
BACKGROUND
The ‘CaP-TB’ project enhanced paediatric TB care through decentralized services, including screening, specimen collection, chest X-rays and implement...
BACKGROUND
Strains of Mycobacterium tuberculosis
This case report presents a rare instance of concomitant splenic tuberculosis (TB), Epstein–Barr virus (EBV)-related T-cell leukemia/lymphoma, and malaria in a 28-year-old pregnant wo...
BACKGROUND
WHO recommends Xpert MTB/RIF Ultra (Ultra) for stool testing for tuberculosis diagnosis in children. Stool processing requires removal of debris and ...
The World Health Organization has called for operational research on all-oral shorter regimens for rifampin-resistant and multidrug-resistant forms of tuberculosis (RR/MDR-TB). We fol...
BACKGROUND
Studies have demonstrated an inverse log-linear relationship between body mass index (BMI) and tuberculosis incidence. However, a person’s BMI is dyn...
People living with HIV (PLHIV) have an increased risk of tuberculosis (TB) and severe COVID-19. TB and COVI...
Tuberculosis (TB) among hospitalized patients is underdiagnosed. This study assessed systematic TB-screenin...
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médec...